Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efinopegdutide - Hanmi Pharmaceutical

Drug Profile

Efinopegdutide - Hanmi Pharmaceutical

Alternative Names: GLP-1/glucagon-agonist; Glucagon-like-peptides/glucagon; Glucagon/GLP-1-agonist; HM-12525A; JNJ 5111; JNJ-64565111; LAPS GLP/GCG; LAPS-GCG/GLP-1; LAPS-GLP-1/GCG; LAPS-GLP/Glucagon; LAPS-OXM; MK-6024; Oxyntomodulin immunoglobulin conjugate

Latest Information Update: 27 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Janssen Pharmaceuticals; Merck & Co
  • Class Antihyperglycaemics; Gastrointestinal hormones; Glucagon-like peptides; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 22 Nov 2023 Merck Sharp & Dohme initiates a phase I pharmacokinetic trial in Healthy volunteers and participants with Hepatic impairment in USA (SC) (NCT06052566)
  • 10 Nov 2023 Updated efficacy data from a phase IIa MK-6024-001 trial in Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 25 Sep 2023 Merck Sharp & Dohme plans a phase I trial in healthy participants and in participants with hepatic impairement (SC, Injection) in October 2023 (NCT06052566)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top